Small and mighty
Turbulent markets and politics - changing the long-term case for healthcare investingone city at a time
Political posturing over drug pricing and the future of the US healthcare system in the run up to the 2020 presidential election is already putting pressure on the healthcare sector but the sell-off shouldn’t put investors off this innovative sector. If they delve deeper, past the large cap pharmaceutical giants, they will find a wealth of companies who are shaking up healthcare and biotech. Paul Major, manager of BB Healthcare investment trust, is one person trying to exploit this fast-evolving landscape.
We start by examining why, despite US politics, there are vast opportunities in healthcare, and then keeping it closer to home, why the NHS needs to embrace huge leaps in technology. Finally, we explore how healthcare is moving on, and why there is no replacement for active fund management.
Articles
Delve into the opportunities in healthcare and biotech, find out how technology is shaping both health and investments, and how to capitalise on this highly-politicised, fast-moving sector.
US healthcare still shines amid political hostilities
The US is a politically hostile environment when it comes to healthcare but despite this, it is also the region with the most potential; with its huge size, growing healthcare market, and single regulator mean it has the best chance of bringing products to market. Investors must, however, be willing to ride out the vagaries of the stock market and ignore the politics around healthcare in order to take advantage of the huge opportunities.
NHS set to stall if it doesn’t get on board with tech
Technology has fundamentally changed the way people live their lives today and the huge leaps made around data analysis must be incorporated into the National Health Service to ensure it is providing the best treatment to patients, however, it is not an IT company and Labour’s plan to prevent outsourcing and prevent the health services from working with outside resource could set it back decades.
NHS set to stall if it doesn’t get on board with tech
Technology has fundamentally changed the way people live their lives today and the huge leaps made around data analysis must be incorporated into the National Health Service to ensure it is providing the best treatment to patients, however, it is not an IT company and Labour’s plan to prevent outsourcing and prevent the health services from working with outside resource could set it back decades.
Healthcare isn’t about big pharma, it’s about innovation
Healthcare stocks have suffered a fall from grace after riding high last year as US 2020 presidential woes come a year early amid a clampdown on drug pricing and even a wholesale shake-up of the US medical system involving expansion of free healthcare. But despite the volatility, there are smaller, innovative medical and biotech companies that are offering returns as well as changing the face of healthcare.
Watch
After a difficult few years, some believe the healthcare industry is primed for a return to form. We look into the political backdrop of healthcare and hear some warnings about new ways to invest into this sector.
Gallery
Panellists
Paul major
Adviser in the investment team – BB Healthcare Trust
Paul has 18 years of experience in the healthcare sector on the sell-side and was top-rated by a number of institutional investment clients. He was one of the first research partners at Redburn, Europe’s leading independent research firm. His work there included bespoke projects on healthcare portfolio construction for several institutions. Paul was previously an analyst and corporate financier at UBS Warburg and studied biochemistry.
Hilary Coghill
Chief Investment Officer – City Asset Management
Hilary began her career in medical research with several highly regarded pharmaceutical companies before moving into investment management over 25 years ago. Since then she has developed a particular expertise in collective investments, offshore products and trust vehicles. She is a founder director of City Asset Management and a key part of the company’s women’s initiative.
Andrew Harradine
Head of Fund Research – EFG Asset Management
Andrew joined EFGAM in December 2010 as Head of Long Only Funds Selection. Prior to this, Andrew spent 14 years at Russell investments as head of European research, focusing on manager research. During his tenure he led the European equity manager research team and was responsible for manager selection supporting €3bn of multimanager funds; he also worked closely with large pension funds providing advice on manager selection. Andrew earned a BComm at the University of Edinburgh and has the ASIP investment qualification.
Patrik Thomas
Investment Director and Head of ESG Investing – Cannacord Genuity Wealth Management
Patrick Thomas sits on Canaccord Genuity Wealth Management’s portfolio construction, fund selection and alternatives committees. He specialises in managing investment portfolios for intermediaries, trusts, charities and pension funds, with a focus on discretionary mandates. He is a chartered wealth manager and a chartered fellow of the CISI.
Garry White
Chief Investment Commentator – Charles Stanley
Garry is Chief Investment Commentator at wealth manager Charles Stanley, and has spent most of his career as a financial journalist. Previously he was the share tipster at the Daily and Sunday Telegraph throughout the financial crisis and prior to that he was European market commentator at Standard & Poor’s during the dot-com bust. He has been looking at equity markets for more than 20 years. Garry is a scientist by training, with a degree in Microbiology and Genetic Engineering. He is an Associate of the Chartered Institute for Securities & Investment (CISI) and a part-qualified banker.
